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Abstract
Background The relation between primary hypertension
(PH), target organ damage (TOD) and oxidative stress
(SOX) is not known.
Methods We assessed SOX in 86 children with PH before
and after 12 months of standard non-pharmacological and
pharmacological therapy based on renin-angiotensin system
blockade.
Results Patients with left ventricular hypertrophy (LVH)
and with carotid intima-media thickness (cIMT) >2SDS
had higher thiobarbituric acid reactive substances (TBARS)
concentrations in comparison to patients without LVH or
with normal cIMT. Patients with metabolic syndrome (MS)
had lower activity of gluthatione peroxidase, higher asym-
metric dimethyloarginine (ADMA) and oxidized LDL cho-
lesterol (oxyLDL) in comparison to patients without MS.
TBARS correlated with left ventricular concentric hypertro-
phy, cIMT, albuminuria and SBP/24 h. ADMA and oxyLDL
correlated with CRP and TG/HDL ratio. After 1 year of
antihypertensive treatment blood pressure, TOD and preva-
lence of MS decreased. TBARS decreased and glutathione
concentrations increased. The decrease of TBARS concen-
tration correlated with the decrease of body mass index
(BMI). Decrease of oxyLDL and ADMA correlated with
increased insulin sensitivity, however markers of SOX did
not correlate with BP decrease.
Conclusion SOX in children with PH correlates with TOD,
metabolic abnormalities, changes in fat amount and im-
provement of insulin sensitivity, but not with BP decrease.
Keywords Primary hypertension . Oxidative stress .
Metabolic syndrome . Insulin resistance . Target organ
damage . Antihypertensive therapy . Children
Introduction
Primary hypertension (PH) is considered as a state of oxi-
dative stress (SOX) that contributes to the development of
arterio- and atherosclerosis and target organ damage (TOD)
[1–4]. Abnormally elevated blood pressure causing hemo-
dynamic insult, and typical intermediate phenotype of PH
consisting of metabolic disturbances, excessive caloric in-
take and physical inactivity, leads to impairment of antiox-
idant defensive capacity [4–6]. As a consequence, reactive
oxygen species cause oxidation of lipids, proteins and DNA
with resultant tissue damage [7]. Furthermore, SOX is
thought to be associated with adipocytokine release and
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renin-angiotensin-aldosterone system (RAAS) activation
[8–10]. Moreover, SOX may lead to insulin resistance and
is one of the elements of metabolic syndrome [11–13].
On the other hand, increased physical activity as a stan-
dard non-pharmacological intervention in hypertensive
patients led to decreased reactive oxygen species generation,
improved nitric oxide bioavailability and vascular function
[14, 15]. Some evidence indicates that angiotensin convert-
ing enzyme inhibitors (ACEi) and angiotensin receptor
blockers (ARB) may reduce oxidative stress and reactive
oxygen species formation in adults with PH [16–19]. How-
ever, there are only single reports on SOX in hypertensive
children [2], and there are no reports describing the relation-
ship between SOX, TOD and antihypertensive treatment in
children with PH. It is still unresolved whether increased
SOX in PH is related to hemodynamic insult or to metabolic
abnormalities which accompany both obesity and PH.
We hypothesized that SOX correlates with severity of
PH, metabolic abnormalities and TOD in children with
PH. Secondly, standard antihypertensive treatment based
on non-pharmacological intervention and blockade of
RAAS causes a decrease of SOX, which in turn correlates
with normalization of metabolic abnormalities and regres-
sion of TOD. To test this hypothesis we assessed changes of
SOX markers in relation to TOD in children with PH before
and after 12 months of standard non-pharmacological and
pharmacological therapy based on ACEi or ARB.
Patients and methods
Patients
The study adhered to the principles of the Declaration of
Helsinki and was approved by the local Ethical Committee.
All parents and children aged above 12 years of age provided
written informed consent.
Detailed characteristics of the study group have been
described previously [20, 21]. Specifically, out of 200 white,
Caucasian children and adolescents admitted consecutively
between 2005–2008 for investigation regarding suspected
arterial hypertension, and who were not yet treated with
antihypertensive drugs and in whom PH was ultimately
diagnosed, 86 children aged 14.1±2.4 (range: 5–17) years
(20 girls and 66 boys) with untreated PH, who completed all
investigative procedures, were included in the recent study.
PH was diagnosed after a thorough clinical and laboratory
diagnostic work-up, according to recently published recom-
mendations [22, 23]. The exclusion criteria were: diagnosis
of secondary hypertension, previous use of antihypertensive
drugs, presence of any significant chronic disease (except
for PH), as well as acute disease including infections in
6 weeks preceding enrollment. Patients with incomplete
biochemical data were also excluded.
In all patients the diagnosis was confirmed by 24 hour
ambulatory blood pressure monitoring (ABPM). ABPM was
performed at the initial visit and after 12 months. Recordings
lasting at least 20 hours with at least 80 % of records were
considered as valid. We used the referential ABPM normative
values published recently to classify patients as having normal
blood pressure, prehypertension, ambulatory hypertension or
severe ambulatory hypertension [24, 25]. Patients who de-
creased systolic blood pressure (SBP) during sleep by more
than 10 % in comparison to day-time SBP values were con-
sidered as dipppers. Ambulatory hypertension was defined as
mean ambulatory SBP above 95th percentile and SBP load
between 25 and 50 %, and severe ambulatory hypertension
was defined as mean ambulatory SBP above 95th percentile
and SBP load above 50 %. Normotension was defined as
mean ambulatory SBP below 95th percentile and SBP load
below 25%. Prehypertensionwas defined asmean SBP below
95th percentile and SBP load in the range 25 – 50 % [25].
Methods
Anthropometrical measurements
In all patients anthropometrical parameters, including body
mass index (BMI), waist circumference (WC), waist-to-hip
ratio (WHR) and waist-to-height ratio (WHTR) were mea-
sured. Obesity and being overweight were diagnosed
according to International Obesity Task Force (IOTF) rec-
ommendations [26].
Laboratory investigations
Blood samples were taken after 12 hours of fasting and were
immediately sent to the laboratory. Plasma lipid peroxides
were determined with the spectrofluorometric method of Yagi,
and results expressed as concentration of thiobarbiturate reac-
tive substance (TBARS). Glutathione and glutathione perox-
idase activity were used as indicators of antioxidant status and
were measured spectrophotometrically in erythrocytes (GSH-
420(Oxis) and GPx-340(Oxis)). Concentration of oxyLDL
and asymmetric dimethyloarginine (ADMA) were measured
by ELISA using a commercially available kit.
Methodology of measurement of other biochemical varia-
bles, including plasma insulin, blood lipids, L-homocysteine,
hsCRP and albuminuria were described previously [20, 21].
Definition of metabolic syndrome
Because some of our patients were below 10 years of age,
metabolic syndrome (MS) was diagnosed when at least 3
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criteria were present (BMI≥95th percentile for age and gender,
arterial hypertension, serum triglycerides>110 mg/dl, fasting
plasma glucose>100 mg/dl or>140 mg/dl at 2 h of oral glu-
cose tolerance test and HDL cholesterol<40 mg/dl [27]).
Intima-media thickness measurements
Carotid and femoral superficial artery intima-media thick-
ness (cIMT and fIMT), and wall cross-sectional area in
carotid artery (WCSA) were evaluated by ultrasound
according to the methodology described previously [28].
The median and standard deviation (SD) of normal values
for cIMT, fIMT and WCSA were obtained from a study of
250 healthy children published elsewhere [28].
Echocardiography (ECHO)
All ECHO examinations were performed by one examiner
blinded to the severity of PH and effectiveness of treatment.
ECHO measurements were performed according to Ameri-
can Society of Echocardiography guidelines [29]. To stan-
dardize left ventricular mass to height, left ventricular mass
index (LVMi) was calculated according to the deSimone
formula [30]. Left ventricular hypertrophy (LVH) was de-
fined as an LVMi value above 95th percentile for age and
gender, based on the pediatric LVMi reference data of
Khoury et al [31]. Relative wall thickness (RWT) was
measured at end diastole as the ratio of posterior wall
thickness plus interventricular septum thickness over LV
internal dimension. A RWT of 0.41, which represents the
95th percentile for RWT for normal children and adoles-
cents, and the 95th percentile for LVMi were used as cutoff
points in evaluation of LV geometry [32].
Antihypertensive treatment
Principles of treatment were already described previously [20,
21]. At enrollment no one patient was treated pharmacologi-
cally nor received any advice about non-pharmacological
treatment. After diagnosis of PH all patients were informed
about principles of non-pharmacological treatment, including
lifestyle changes, increased physical activity and dietary mod-
ifications including salt avoidance, and were referred to an
external consultant. All patients were encouraged to increase
general physical activity up to 90 minutes daily including
sport, walking, climbing stairs, etc. The character of activity
(playing football, jogging, aerobic, walking, biking, etc.) was
chosen by patients according to personal preferences. Dietary
modifications were based on significant reduction of salt use
both by patients and familymembers, and significant reduction
of sweets.
Pharmacological treatment was immediately started in
patients who had a significant TOD and/or severe ambulatory
hypertension. BP was checked at the 3rd and the 6th month
during ambulatory visits. If after 3 or 6 months office BP was
still in the hypertensive range ABPM was done. In patients
who still had ambulatory or severe ambulatory hypertension,
pharmacotherapy was started. Finally, ABPM was performed
after 12 months of treatment.
Drug therapy was based on the ACEi enalapril (0.2 –
0.3 mg/kg/day bid). Patients who had asthma or who did not
tolerate ACEi were prescribed angiotensin 2 receptor type 1
blocker (ARB) losartan in a dose of 0.7 – 1 mg/kg/day in
one or two daily doses.
All patients were evaluated at regular 3 months intervals
during routine ambulatory, out-patient visits. Compliance to
recommended lifestyle modifications was assessed by inter-
view with patients and parents. When the antihypertensive
effect was inadequate, amlodipine as the second drug was
introduced and in patients treated only with lifestyle inter-
vention, therapy with ACEi, ARB or amlodipine was
started. Patients who were still hypertensive after 6 months
and/or fulfilled the criteria of stage 2 hypertension based on
home and casual BP measurements were prescribed meto-
prolol in a dose 0.5 mg/day as the third drug.
Statistics
Because the analyzed groups included subjects of different
age and gender, BMI and WC values were expressed both as
absolute values and as SDS for age and gender. LVM values
in g were standardized to height in meters2.7. The change of
measured parameters was expressed as a delta value (Δ), ie
the difference between measurement at 12 months and at
start of treatment. Homogeneity of variance was checked
with the Levene test. Continuous variables with a normal
distribution were compared by the Student’s t-test for inde-
pendent variables. Continuous values with non-normal dis-
tribution were compared by the Mann–Whitney U test.
Comparison between groups was evaluated with an
ANOVA test. Measurements taken at the start and after
12 months of treatment were compared using the Wilcoxon
test. Dichotomous variables were compared using the Chi-
square test, and change in prevalence during treatment was
analyzed with the McNemar test. Correlation analysis was
done with the Spearman test. P values less than 0.05 were
regarded as statistically significant.
Results
At start of treatment 67.4 % of patients were obese or
overweight and their mean (±SD) BMI-SDS was +1.9
±1.8. Metabolic syndrome was diagnosed in 13 patients
(15.1 %) [20, 21] (Table 1).
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Relationship between SOX markers, BP, TOD
and metabolic abnormalities at baseline
36 (41.9 %) patients with severe ambulatory HT had signif-
icantly lower concentrations of GSH in comparison to 50
(58.1 %) patients with ambulatory HT (748.7 (365.2-862.5)
vs 773.6 (361.5 -889.4) μmol/l, p<0.01). 40 patients with
non-dipping status had lower values of GPX than patients
with normal nocturnal fall of BP (31,2 ±1.7 vs 32.5 ±3.3 U/g
Hb; p00.01).
40 patients with LVH had higher values of TBARS
compared to 46 patients without LVH (0.33 (0.14-1.28) vs
0.24 (0.16-1.25) μmol/l, p00.02) (Figure 1). Similarly, 20
(24 %) patients with cIMT >2 SDS had greater TBARS
concentration than patients showing cIMT<2 SDS (0.36
(0.20-1.25) vs 0.26 (0.14-1.05) μmol/l, p<0.01) and not
significantly higher ADMA concentration (0.71 (0.25-
1.37) vs 0.49 (0.17-1.45) μmol/l, p00.1) and GPX activity
(32.0 (26.2-39.2) vs 31.4 (25.4-39.9) U/gHb, p00.1).
Patients with MS had lower activity of GPX, and higher
concentrations of ADMA and oxyLDL when compared to
patients without MS (Table 2, Figure 2, 3).
TBARS concentrations correlated with LVMi, RWT,
cIMT, cIMT-SDS, WCSA, urinary albumin excretion and
SBP/24 h (Table 3). ADMA and oxyLDL concentrations
correlated with hsCRP and TG/HDL ratio. GPX activity
correlated with TG/HDL ratio and nocturnal fall of blood
pressure.
SOX markers did not differ between overweight/obese vs
normal weight patients, between patients with visceral obesity
and without, and between patients with positive vs negative
family history of cardiovascular disease (data not shown).
Follow- up characteristics
As described previously, after 1 year of antihypertensive treat-
ment, there was a significant decrease of blood pressure,
prevalence of TOD and of MS, and improvement of some
metabolic abnormalities, such as a decrease of hsCRP, uric
acid, total – and LDL cholesterol concentration and a decrease
of visceral fat amount [20]. Compared to baseline, TBARS
concentrations decreased and GSH increased (Table 1,
Figure 4).
SOX markers did not correlate with blood pressure
changes. 64 (73.8 %) patients who had lowered blood pres-
sure, did not have significantly different concentrations of
ADMA and oxyLDL.
Table 1 Descriptive demographic, clinical and laboratory data of oxidative stress and inflammatory markers at baseline and after 12 months of
treatment
Baseline After 12 months of treatment P
Patients with MS (%) 13 (15 %) 6 (7 %) p00.07, chi203.27
Patients with normotension (%) 0 54 (62.8 %) p00.0001, chi2075.80
Patients with prehypertension (%) 0 10 (11.6 %) p00.003, chi208,60
Patients with ambulatory HT (%) 50 (58.1 %) 21 (24.4 %) p00.00001, chi2027.03
Patients with severe HT (%) 36 (41.9 %) 1 (1.2 %) p00.00001, chi2033.03
Patients with LVH (%) 40 (46.5 % ) 24 (27.9 % ) p00.003; chi2 08.65
hsCRP (mg/dl) 0.86 (0.02-4.10) 0.41 (0.10-3.90) <0.001
GSH (μmol/l) 763.4 (361.5-889.4) 778.1 (638.1-825.6) <0.01
GPX (U/gHb) 31.6( 25.4-39.9) 31.6 (27.6-37.2) ns
TBARS (μmol/l) 0.56 (0.14-2.73) 0.25 (0.14-1.28) <0.001
ADMA (μmol/l) 0.54 (0.17-1.45) 0.56 (0.18-1.4) ns
oxyLDL (mU/ml) 340.1 (104.3-1364.7) 367.5 (110.8-1409.8) ns
Abbreviations: MS- metabolic syndrome, hsCRP – high-sensivity C-reactive protein, GSH - reduced glutathione, GPX – glutathione peroxidase










LVH (-) LVH (+)
TBARS  (µmol/l)
TBARS  (µmol/l)
Fig. 1 Comparison in median of thiobarbituric acid reactive substan-
ces (TBARS) concentrations between patients with- and without left
ventricular hypertrophy (LVH) (p<0.01)
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Patients with regression of TOD in comparison to
patients with progression/no change of TOD did not differ
significantly regarding changes of SOX parameters, howev-
er patients who had decreased fIMT-SDS also had decreased
oxyLDL concentrations in comparison with patients in
whom fIMT-SDS increased or did not change (ΔoxyLDL:
- 56.0 (−242.2-460.3) vs 82.3 (−59.1-809.5) mU/ml, p0
0.01). Patients in whom LVMi decreased had no significant
change in oxyLDL (ΔoxyLDL: -26.5 (−626.1-810.1) vs
42.2 (−253.1-804.2) mU/ml) and ADMA (ΔADMA: -0.10
(−0.91-0.91) vs 0.18 (−0.25-0.53) μmol/l, both p00.07)
compared to patients who did not have decreased LVMi.
Changes in SOX markers correlated with changes in
insulin resistance and lipids. ADMA and oxyLDL concen-
trations decreased and GPX activity showed no significant
change in patients who lowered TG/HDL ratio in
comparison to patients with stabilization/increase of TG/
HDL ratio (Δ ADMA: -0.16 (−0.58-0.91) vs 0.12 (−0.91-
0.57) μmol/l, p00.05, ΔoxyLDL: -59.1 (−626.6-460.3) vs
100 (−295.6-810.1) mU/ml, p00.008, ΔGPX: 0.2 (−7.2-
10.3) vs −0.1 (−9.1-5.3) U/gHb, p00.1). Patients in whom
ADMA concentrations decreased at follow-up, had lower
insulin and HbA1C concentrations, HOMA-IR, TG/HDL
and LDL/HDL ratios when compared to patients with in-
crease/stabilization of ADMA (Table 4).
The decrease of TBARS concentrations correlated with a
decrease of BMI (p00.04, r00.22) but there was no statis-
tically significant correlation with a decrease of WC (p00.1,
r00.20).
The step-wise regression analysis did not reveal any
significant predictors of decrease of TBARS concentrations
and of increase of GSH.
Table 2 Baseline biochemical characteristics of patients with metabolic syndrome (MS[+]) and without metabolic syndrome (MS[−])
MS[−] N073 (86.9 %) MS[+] N013 (15.1 %) p
HbA1C (%) 5.3 (4.2-6.8) 5.3 (4.1-6.4) ns
TG/HDL 1.76 (0.67-4.96) 2.74 (1.65-12.9) 0.001
HOMA-IR 2.67 (0.94-9.74) 2.73 (2.04-8.77) 0.11
hsCRP (mg/dl) 0.83 (0.02-4.15) 1.2 (0.14-3.94) ns
homocysteine(μmol/l) 9.84 ±2.52 10.7 ±1.34 ns
Uric acid (mg/dl) 5.3 ±1.2 6.8 ±1.2 <0.001
GSH (μmol/l) 761.7 (361.5-862.5) 765.1 (658.1-889.4) ns
GPX (U/g Hb) 31.8 (25.4-39.9) 30.5 (26.2-38.7) <0.01
TBARS (μmol/l) 0.31 (0.14-1.25) 0.26 (0.18-1.28) ns
ADMA (μmol/l) 0.49 (0.17-1.37) 0.88 (0.21-1.45) <0.01
oxyLDL (mU/ml) 309.0 (104.3-1255.2) 489.9 (195.7-1364.7) 0.03
Abbreviations: MS –metabolic syndrome, n – number of patients, HbA1C – glycated hemoglobin concentration, TG/HDL – triglicerydes to high density
lipoprotein cholesterol ratio, HOMA-IR – homeostasis model assessment for insulin resistance, hsCRP – high-sensivity C-reactive protein, GSH - reduced
glutathione, GPX – glutathione peroxidase activity ,TBARS – thiobarbituric acid reactive substances, ADMA – serum asymmetric dimethyloarginine,















Fig. 2 Comparison in median of asymmetric dimethyloarginine












Fig. 3 Comparison in median of oxyLDL concentrations between
patients with- and without metabolic syndrome (p<0.01)
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Discussion
The main finding of the study is that in newly-diagnosed
hypertensive children, the severity of hypertension, TOD, met-
abolic abnormalities and immune activity were all associated
with the magnitude of oxidative stress. The second finding is
that standard antihypertensive treatment based on lifestyle
modifications and/or blockade of the renin-angiotensin system
caused a decrease of SOX and improved antioxidative defense.
Further, the changes of SOX after 1 year of treatment
correlated with regression of TOD and increased insulin sen-
sitivity, but not directly with decrease of blood pressure.
Several reports have evaluated antioxidative defense and
SOX in patients with PH and cardiovascular disease [1–6,
10, 11, 16–19]. However, in studies where classification of
blood pressure status was based on clinical measurements it
was found that SOX does not correlate with severity of
hypertension, and even is not increased in adults with mild
to moderate PH [33]. In contrast, we used ABPM to classify
severity of hypertension and we found that children with
severe ambulatory hypertension, ie those who are at higher
risk of LVH, had significantly lower GSH concentrations
and non-dippers had lower GPX activity. This may explain
why, in contrast to other reports, we found significant differ-
ences regarding SOX in relation to stage of hypertension.
The corresponding finding is a strict relationship between
SOX and LVH and arterial injury. Finding that SOX markers
were associatedwith blood pressure status and TOD expressed
as LVH and/or cIMT and fIMT thickening does not indicate
any causation. The common pathway may be metabolic ab-
normalities. Baykal et al found that, despite a similar decrease
of blood pressure, only ACEi and ARBs caused a significant
decrease of SOX accompanied by decrease of total cholester-
ol, triglycerides and LDL-cholesterol concentrations [19]. It is
in line with the finding that normalization of metabolic abnor-
malities and immune activity was the main determinant of
regression of TOD in hypertensive children [20, 21].We found
Table 3 Correlations between
parameters of oxidative stress
and dependent variables at base-
line (Spearman correlation
analysis)
Abbreviations: ADMA – serum
asymmetric dimethyloarginine;
cIMT –carotid intima media
thickness; fIMT- femoral intima
media thickness; hsCRP – high-
sensivity C- reactive protein;
GSH - reduced glutathione;
GPX – glutathione peroxidase ac-
tivity; LVMi – left ventricular
mass index; oxyLDL- oxidized
low density lipoprotein cholester-
ol; RWT – relative wall thickness;
SBP/24 h – mean systolic blood
pressure in 24 hour-ambulatory
blood pressure monitoring;
TBARS – thiobarbituric acid re-
active substances;TG/HDL –
triglicerydes to high density lipo-
protein cholesterol ratio;
WCSA –wall cross sectional area;
WHR – waist-hip ratio
SOX parameters Dependent variables






Urinary albumin excretion/24 h p<0.05, r00.21
fIMT p00.02, r0−0.28
fIMT-SDS p00.01 r0−0.30
GPX nocturnal fall of SBP P00.03, r0−0.235
TG/HDL p00.003, r0−0.31
WHR P00.1, r0−0.311





oxyLDL hsCRP P<0.001, r00.662
TG/HDL P<0.0001, r00.382
GPX P<0.05, r0−0.25








TBARS (1) TBARS (2)
Fig. 4 Comparison of medians of thiobarbituric acid reactive substan-
ces (TBARS) concentrations at start (TBARS1) - and after 12 months
(TBARS2) of the study (p<0.0001)
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that children with MS had lower GPX activity and higher
ADMA and oxyLDL values in comparison to children without
MS. The relationship between MS and SOX has already been
described byKelly et al, who found higher SOX in overweight
children with MS compared to normal and overweight coun-
terparts without metabolic abnormalities [34]. Siemianowicz
et al revealed an association between ADMA and hsCRP
levels and insulin resistance [35]. In our study we found a
correlation between ADMA and markers of insulin resistance,
and the decrease of ADMA concentrations correlated with a
decrease of both TG/HDL ratio and direct markers of insulin
resistance such as insulin, HbA1c and HOMA-IR. These
relationships, observed also in adult patients, suggest that
ADMA is the element that links insulin resistance and the
arterio-/atherosclerotic process [11, 36, 37]. Increased ADMA
concentrations in hypertensive children were found by
Goonasekara et al [38]. ADMA is only an indirect marker of
SOX, because dimethylarginine dimethylaminohydrolases
metabolizing ADMA are inactivated by reactive oxygen spe-
cies [39]. However, concentrations of ADMA are parallel to
direct SOX markers as was also found in our study. Indepen-
dent of vascular action, impaired nitric acid (NO) bioavailabil-
ity can be related to a cellular defect in skeletal muscles, where
NO regulates metabolic and contractile processes including
among others, basal glucose transport [40].
It has been shown that there is relationship between
genetic polymorphisms of NADPH oxidase and extent of
atherosclerosis [41]. Decrease of GSH in rats caused signif-
icant increase of blood pressure, and increased antioxidative
capacity diminished the hypertensive effect induced by
GSH decrease [42]. However, there is only weak evidence
that antioxidants may lower blood pressure [43]. One pos-
sible explanation is that SOX is secondary to hemodynamic
and metabolic injury to the arterial wall and left ventricle.
This is strengthened by strict relationships between changes
of metabolic parameters and BMI with SOX markers. Al-
though we found correlation between changes in BMI and
changes in TBARS concentrations at follow-up, at baseline
obese patients did not differ from normal-weight patients
regarding SOX markers. This may be due to the narrow
range of BMI in our patients. On the other hand, studies
including subjects with wide BMI ranges from 18 to 45,
have found that obese subjects had greater lipid peroxides
concentrations in comparison with lean subjects [44]. De-
spite many correlations we did not find any predictors of
SOX or predictors of change in SOX during treatment,
which suggests that there are other modifying factors linking
hypertension, metabolic abnormalities and TOD.
The main limitation of our study is the relatively low
number of patients. Moreover, due to ethical reasons, we
could not separate the effects of antihypertensive drugs and
non-pharmacological treatment, because healthy nutrition and
regular physical activity were recommended for all patients.
The other limitation of our study is its observational design
and lack of normotensive and BMI-matched control group.
Therefore, although we found significantly increased oxida-
tive stress in hypertensive children, and especially among
children with LVH and arterial injury, we did not find a
Table 4 Comparison between patients who decreased ADMA concentrations and patients with stable/increased ADMA concentrations after
12 months of treatment
Decrease of ADMA n024 Increase/stabilization of ADMA n020 p
Δ HOMA-IR −0.41(−3.71-1.58) 0.31 (−2.38-1.82) 0.17
Δ HbA1C (%) −0.1 (−1.1-4.5) 0.05 (−1.4-2) 0.03
ΔTG/HDL −0.28 ( −5.77-1.76) 0.14 (−0.90-4.41) 0.02
Δ homocysteine −1.02±3.21 1.13 ±2.29 0.02
Δ uric acid (mg/dl) −0.38±1.14 0.04 ±0.82 0.11
ΔLDL/HDL −0.61 (−1.51-1.18) 0.21 (−0.70-1.48) 0.0002
ΔoxyLDL(mU/ml) −98.95 (−626.14 – 154) 139 (−253.1-818.1) 0.0001
Δ RWT (mm) −0.03 (−0.35-0.04) 0.007 (−0.15-0.15) 0.04
HOMA-IR at follow-up 2.12 (1.60-6.45) 3.32 (1.93-5.43) 0.008
Glu[0] (mg/dl) at follow-up 86 (71–95) 87 (75–91) 0.02
Ins[0] (mU/ml) at follow-up 10.7 ( 7,3-29) 15.7 (9–159) 0.003
LDL/HDL at follow-up 2.25 (1.50-4.11) 2.83 (1.85-3.70) 0.02
ADMA at follow-up (μmol/l) 0.505 (0.30-1.19) 0.79 (0.47 -1.37) 0.02
oxyLDL at follow-up (mU/ml) 356.12 (131–935.6) 388.7 (129.3-1409.8) ns
Abbreviations: n - number of patients, Glu[0] – fasting plasma glucose; HOMA-IR – homeostasis model assessment for insulin resistance, HbA1C –
glycated hemoglobin concentration, Ins[0] – plasma fasting insulin concentration; TG/HDL – triglicerydes to high density lipoprotein cholesterol ratio,
oxyLDL- oxidized low density lipoprotein cholesterol, ADMA – serum asymmetric dimethyloarginine, RWT – relative wall thickness, glucose[0] –
fasting glucose concentration, insulin [0] –fasting insulin concentration, insulin[120] – insulin concentration after 120 min. of oral glucose ingestion
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causative mechanism or explain the influence of obesity and
hypertension, separately. On the other hand, the link between
increased insulin sensitivity and SOX reduction underlines the
importance of non-pharmacological treatment, first of all
based on an increase of physical activity.
Conclusions
We have shown the relation between oxidative stress and the
severity of hypertension, TOD andmetabolic disorders typical
for PH. Decrease of SOX correlated with regression of TOD
and normalizations of metabolic abnormalities and immune
activity, but not with hypotensive effect of treatment. This
finding underlines the importance of immuno-metabolic fac-
tors in the pathogenesis of hypertensive TOD and indicates
that antihypertensive treatment should be focused both on
hypotensive effects and metabolic abnormalities.
Funding sources The study was in part financially supported by
Ministry of Science and Higher Education grant: 5412/B/P01/2010/39.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Watanabe T, Yasunari K, Nakamura M, Maeda K (2006) Carotid
artery intima-media thickness and reactive oxygen species formation
by monocytes in hypertensive patients. J Human Hypertens 20:336–
340
2. Turi S, Friedman A, Bereczki C, Papp F, Kovàcs J, Karg E,
Németh I (2003) Oxidative stress in juvenile essential hyperten-
sion. J Hypertens 21:145–152
3. Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimäki T, Solakivi T,
Rönnemaa T, Raitakari OT (2005) Carotid artery intima-media
thickness in children with type 1 diabetes. Diabetes 51:493–498
4. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S,
Corrocher R (1998) Anti-oxidant status and lipid peroxidation in
patients with essential hypertension. J Hypertens 16:1267–1271
5. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G,
Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ, Investigators
AtheroGene (2003) Glutathione peroxidase 1 activity and cardio-
vascular events in patients with coronary artery disease. N Eng J
Med 349:1605–1613
6. Pedro-Botet J, Covas MI, Martin S, Rubies-Prat J (2000) De-
creased endogenous antioxidant enzymatic status in essential hy-
pertension. J Hum Hypertens 14:343–345
7. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J
(2007) Free radicals and antioxidants in normal physiological
functions and human disease. Int J Biochem Cell Biol 39:44–84
8. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are
oxidative stress activated signaling pathways mediations of insulin
resistance and beta cell dysfunction? Diabetes 52:1–28
9. Sinaiko AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu
S, Tracy R, Jacobs DR (2005) Relation of body mass index and
insulin resistance to cardiovascular risk factors, inflamatory
factors, and oxidative stress during adolescence. Circulation
111:1985–1991
10. Kristal B, Shutz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G,
Weissman I, Shasha SM, Sela S (1998) Participation of peripheral
polymorphonuclear leukocytes in patients with essentials hyperten-
sion. Am J Hypertens 11:921–928
11. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G,
Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F,
Sesti G (2010) Endothelial dysfunction, ADMA and insulin resistance
in essentials hypertension. Int J Cardiol 142:236–241
12. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N
(1998) Prolonged oxidative stress impairs insulin-induced GLUT-4
translocation in 3 T3-L1 adipocytes. Diabetes 47:1562–1569
13. Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM,
Jacobs DR (2009) Oxidative stress and insulin resistance. The
coronary artery risk development in young adults study. Diabetes
32:1302–1307
14. Melikoglu MA, Kaldirimci M, Katkat D, Sen I, Kaplan I, Senel K
(2008) The effect of regular long term training on antioxidant
enzymatic activities. J Sports Med Phys Fitness 48:388–390
15. Whyte JJ, Laughlin MH (2010) The effects of acute and chronic
exercise on the vasculature. Acta Physiol 199:441–450
16. Yagi S, Morita T, Katayama S (2004) Combined treatment with an
AT1 receptor blocker and angiotensin converting enzyme inhibitor
has an additive effect on inhibiting neointima formation via im-
provement of nitric oxide production and suppression of oxidative
stress. Hypertens Res 27:129–135
17. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T,
Kawasaki H, Takahashi H, Uno T, Tsukamoto T, Hiei K, Fujiwara
H (2008) Candesartan decreases carotid intima-media thickness by
enhancing nitric oxide and decreasing oxidative stress in patients
with hypertension. Hypertens Res 31:271–279
18. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J,
Asada A (2004) Comparative effects of valsartan versus amlodipine
on left ventricular mass and reactive oxygen species formation by
monocytes in hypertensive patients with left ventricular hypertrophy.
J Am Coll Cardiol 43:2116–2123
19. Baykal Y, Yilmaz MI, Celik T, Gok F, Rehber H, Akay C, Kocar IH
(2003) Effects of antihypertensive agents, alpha receptor blockers,
beta blockers, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers and calcium channel blockers, on oxidative stress. J
Hypertens 21:1207–1211
20. Litwin M, Niemirska A, Śladowska-Kozłowska J, Wierzbicka A,
Janas R, Wawer ZT, Wiśniewski A, Feber J (2010) Regression of
target organ damage in children and adolescents with primary
hypertension. Pediatr Nephrol 25:2489–2499
21. Śladowska-Kozłowska J, Litwin M, Niemirska A, Wierzbicka A,
Wawer ZT, Janas R (2011) Change in left ventricular geometry
during antihypertensive treatment in children with primary hyper-
tension. Pediatr Nephrol 26:2201–2209
22. National High Blood Pressure Education Program Working Group
on High Blood Pressure in Children and Adolescents (2004) The
Fourth Report on Diagnosis, Evaluation and Treatment of High
Blood Pressure in Children and Adolescents Pediatrics 114:555–
576
23. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti
C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher
W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti
A, European Society of Hypertension (2009) Management of high
blood pressure in children and adolescents: recommendations of
the European society of hypertension. J Hypertens 27:1719–1742
24. Wühl E, Witte K, Soergel M, Mehls O, Shaefer F, German Working
Group on Pediatric Hypertension (2002) Distribution of 24-h
1950 Pediatr Nephrol (2012) 27:1943–1951
ambulatory blood pressure in children: normalized reference values
and role of body dimensions. J Hypertens 20:1995–2007
25. Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, JacobsonM,
Mahoney L, McCrindle B, Mietus-Snyder M, Steinberger J, Daniels
S, American Heart Association Atherosclerosis, Hypertension, and
Obesity in Youth Committee (2008) Ambulatory blood pressure
monitoring in children and adolescents recomendations for standard
assessment. A scientific statement from the American heart associa-
tion atherosclerosis, hypertension, and obesity in youth committee of
the council on cardiovascular disease in the young and the council for
high blood pressure research. Hypertension 52:433–451
26. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a
standard definition for child overweight and obesity worldwide:
international study. BMJ 320:1240–1243
27. Litwin M, Śladowska J, Antoniewicz J, Niemirska A, Wierzbicka A,
Daszkowska J, Wawer ZT, Janas R, Grenda R (2007) Metabolic
abnormalities, insulin resistance and metabolic syndrome in children
with primary hypertension. Am J Hypertens 20:875–882
28. Jourdan C, Wühl E, Litwin M, Fahr K, Trelewicz J, Jobs K,
Schenk JP, Grenda R, Mehls O, Tröger J, Schaefer F (2005)
Normative values of intima-media thickness and distensibility of
large arteries in healthy adolescents. J Hypertens 23:1707–1715
29. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E,
Sachs I, Reichek N (1986) Echocardiographic assessment of left
ventricular hypertrophy: comparison to necropsy findings. Am J
Cardiol 57:450–458
30. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de
Divitiis O, AldermanMH (1992) Left ventricular mass and body size
in normotensive children and adults: assessment of allometric rela-
tions and impact of overweight. J Am Coll Cardiol 20:1251–1260
31. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-
specific reference intervals for indexed left ventricular mass in
children. J Am Soc Echo 22:709–714
32. Daniels SR, Meyer RA, Liang Y, Bove KE (1998) Echocardiograph-
ically determined left ventricular mass index in normal children,
adolescents and young adults. J Am Coll Cardiol 12:703–708
33. Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iraki A, Sáez
GT (2003) Antioxidant activities and oxidative stress byproducts
in human hypertension. Hypertension 41:1096–1101
34. Kelly AS, Steinberger J, Kaiser DR, Olson TP, Bank AJ, Dengel
DR (2006) Oxidative stress and adverse adipokine profile charac-
terize the metabolic syndrome in children. J Cardiometab Syndr
1:248–252
35. Siemianowicz K, Gmiński J, Francuz T, Wójcik A, Posielezna B
(2006) Activity of antioxidant enzymes in children from families at
high risk of premature coronary heart disease. Scand J Clin Lab
Invest 63:151–158
36. Sydov K, Mondon CE, Cooke JP (2005) Insulin resistance: potential
role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc
Med 10:35–43
37. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL,
Cooke JP, Reaven GM, Tsao PS (2002) Relationship between insulin
resistance and an endogenous nitric oxide synthase inhibitor. J Am
Med Assoc 287:1420–1426
38. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon
MJ (1997) Nitric oxide synthase inhibitors and hypertension in
children and adolescents. J Hypertens 15:901–909
39. Palm AJP, Onozato ML, Luo Z, Wilcox CS (2007) Dimethylarginine
dimethylaminohydrolase (DDAH): expression, regulation, and func-
tion in the cardiovascular and renal systems. Am J Physiol Heart Circ
Physiol 293:H3227–H3245
40. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A (1997)
Expression of nitric oxide synthase in skeletal muscle: a novel role
for nitric oxide as a modulator of insulin action. Diabetes 46:1691–
1700
41. Moreno MU, San José G, Fortuño A, Beloqui O, Díez J,
Zalba G (2006) The C242T CYBA polymorphism of NADPH
oxidase is associated with essential hypertension. J Hypertens
24:1299–306
42. Vaziri ND, Wang XQ, Oveisi F, Rad B (2000) Induction of oxida-
tive stress by glutathione depletion causes severe hypertension in
normal rats. Hypertension 36:142–146
43. Touyz RM (2004) Reactive oxygen species, vascular oxidative
stress, and redox signaling in hypertension: what is the clinical
significance? Hypertension 44:248–252
44. Brown LA, Kerr CJ, Whiting P, Finer R, McEneny J, Ashton T
(2009) Oxidant stress in healthy normal-weight, overweight and
obese individuals. Obesity 17:460–466
Pediatr Nephrol (2012) 27:1943–1951 1951
